Cambridge's SynDevRx Reveals Breakthrough In Cancer Treatment Targeting Metabolic Hormones

In a significant stride towards advancing cancer treatment, Cambridge-based biotechnology firm SynDevRx has unveiled findings from its latest research on evexomostat/SDX-7320. This optimized MetAP2 inhibitor, as detailed in their recent publication, showcases a leap in the fight against cancer with its enhanced activity, superior properties, and a safer profile. The focus of this innovation is the methionine aminopeptidase 2 (MetAP2) enzyme, a critical facilitator in the proliferation and metastatic spread of cancer cells. The research underlines evexomostat's precision in targeting this enzyme, alongside its potent anti-tumor and anti-metastatic efficacy demonstrated in preclinical cancer models.

Peter Cornelius, Senior Director of Translational Research at SynDevRx and lead author of the study, shared his excitement about the development of evexomostat. "This represents a significant step forward in our understanding and treatment of cancer," he stated. Bradley Carver, CEO of SynDevRx, also highlighted the importance of this achievement, pointing to its potential to markedly improve the lives of individuals battling cancer.

The company's innovative approach involves a polymer conjugation technique that has led to the creation of an inhibitor with not only improved activity but also better overall properties and safety compared to its predecessors. This advancement is part of SynDevRx's broader commitment to metabo-oncology, an emerging field that explores how metabolic pathways influence cancer and its treatment.

Further demonstrating their dedication to bringing evexomostat to patients, SynDevRx has successfully completed a Phase I dose-escalation safety trial. Currently, the company is conducting two open/enrolling clinical trials specifically targeting breast cancer patients. These steps underscore SynDevRx's ongoing efforts to leverage their expertise for impactful cancer treatments.

The development of evexomostat represents a promising avenue in cancer therapy, particularly for those suffering from breast cancer. With its targeted approach and preclinical success, SynDevRx's work offers hope for more effective and safer cancer treatments in the near future.